Aktis Oncology (AKTS) said Thursday it priced its upsized initial public offering of about 17.7 million shares at $18 each and expects its shares to begin trading on the Nasdaq Global Select Market on Friday.
Underwriters have been granted a 30-day option to buy up to about 2.7 million additional shares. Gross proceeds are estimated to be around $318 million, excluding the proceeds from the exercise of the option.
The company is offering all the shares in the IPO, which is expected to close on Jan. 12.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments